We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-11.43%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
AUM
$193M
AUM Growth
-$41.4M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
8
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$60.4M 31.36%
9,671,643
PHVS icon
2
Pharvaris
PHVS
$2.28B
$26.2M 13.57%
3,246,926
LYEL icon
3
Lyell Immunopharma
LYEL
$318M
$23.6M 12.25%
500,000
ACRS icon
4
Aclaris Therapeutics
ACRS
$715M
$22.7M 11.79%
2,808,034
KURA icon
5
Kura Oncology
KURA
$793M
$22.6M 11.74%
1,849,947
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.7B
$18.5M 9.59%
875,000
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$15.6M 8.09%
1,787,094
QSI icon
8
Quantum-Si Incorporated
QSI
$153M
$3.12M 1.62%
1,771,249

Similar funds

Foresite Capital Management IV's Q1 2023 Portfolio in Review

As of Q1 2023, Foresite Capital Management IV held 8 positions worth $193M, down 18% from $234M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Foresite Capital Management IV opened no new positions and made no exits, leaving the 8-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's ten largest holdings make up 100% of its $193M portfolio in Q1 2023.
  • Foresite Capital Management IV opened 0 new positions and closed 0 in Q1 2023.
  • Foresite Capital Management IV's portfolio value fell 18% quarter-over-quarter to $193M.

Based on Foresite Capital Management IV's 13F filing for Q1 2023, filed 12 May 2023.